The inhibition of hsa-miR-30a may retard tumor progression by decreasing Beclin-1 and ATG5 expression and inhibiting autophagy, thereby sensitizing the tumor cells to the drug therapy [59,60]. This evidence concerns the gene BECN1 and neoplasm.